TradeUP Acquisition Corp. (UPTD) Adds $6.8M PIPE to Estrella Deal
by Nicholas Alan Clayton on 2023-07-26 at 8:55am

TradeUP (NASDAQ:UPTD) announced in an 8-K this morning that it has added a $6.8 million PIPE to its combination with Estrella Biopharma, which will wipe an equal amount of debt from its books.

Eureka Therapeutics, which was owed $6.8 million by Estrella, will instead receive 680,000 Class B units, each consisting of one common TradeUp share and one preferred share.

While these common TradeUp shares will convert to Estrella shares at the business combination’s close, the preferred shares will do so six months later. These will convert to a number of shares equal to $10 minus the greater of the stock’s last closing price or its 20-day VWAP. In no case will the conversion price be less than $4.15.

Eureka has also agreed to a one-year lock-up for all shares received as a part of this arrangement. So, it gains some downside protection and higher upside on its debt while Estrella gets to enter the public markets with a cleaner balance sheet.

TradeUp initially announced its $398 million combination with Estrella Biopharma in October 2022. Emeryville, California-based Estrella is developing three potential cancer therapies aimed at improving the effectiveness of T-cell treatments.

The SPAC secured a one-year extension of its transaction deadline earlier this month to continue working on the deal and will contribute $0.05 per share monthly moving forward. Redemptions from this vote expanded its total shares redeemed to 83.1%, however, leaving it with just $7.9 million in trust.

TradeUp must provide at least $20 million in cash in order for the deal to close. In April, White Lion Capital agreed to purchase up to $50 million in shares of the combined company after close through a common stock purchase agreement.

Recent Posts
by Nicholas Alan Clayton on 2024-02-26 at 1:45pm

News and Rumors PR: Medtech firm Agiliti (NYSE:AGTI) has agreed to be acquired by an affiliate of private equity firm Thomas H. Lee Partners (THL) at $10 per share and an enterprise value of $2.5 billion. This represents a 43% premium over the company’s 90-day VWAP and returns it to 100% ownership by THL five...

by Nicholas Alan Clayton on 2024-02-26 at 7:42am

At the SPAC of Dawn The last week of February is to host a moderate amount of SPAC votes and also the potential for some market-moving data releases. Shareholders for five SPACs are to consider extensions this week and seven more SPACs have scheduled completion votes. But, among the more interesting events on the agenda...

by Kristi Marvin on 2024-02-24 at 11:45am

Terms Tracker for the Week Ending February 23, 2024 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. As expected, new issuance filings were quiet this week.  But, deal announcements were surprisingly active.  Four more SPACs announced combinations in a shortened holiday week...

by Nicholas Alan Clayton on 2024-02-23 at 2:26pm

Pyrophyte (NYSE:PHYT) faced a major regulatory setback for its combination with mining firm Sio Silica this week, but a recent analogous SPAC deal could provide some encouragement for a path forward. Sio Silica is working to develop a high-grade silica mine in the Vivian Sands outside Winnipeg, Canada and it inked the $708 million combination...

by Nicholas Alan Clayton on 2024-02-23 at 1:37pm

News and Rumors JD Supra: Securities class action lawsuits against SPACs and de-SPACs increased only slightly in 2023 with 27 after 2022 saw 24 and 2021 – 33. Lawsuits concerning the de-SPACing process itself dropped precipitously, however, representing just 21% of cases as compared to 69% in the previous two years and 80% in 2020....


Copyright © 2023 SPACInsider, Inc. All Rights Reserved